(Q53341633)

13 May 2018

title

Prediction of alpha-blocker response in men with benign prostatic hyperplasia by magnetic resonance imaging. (English)

1 reference

13 May 2018

main subject

prostatic hypertrophy

1 reference

Mimata H

1

1 reference

13 May 2018

Nomura Y

2

1 reference

13 May 2018

Kasagi Y

3

1 reference

13 May 2018

Satoh F

4

1 reference

13 May 2018

Emoto A

5

1 reference

13 May 2018

Li W

6

1 reference

13 May 2018

Douno S

7

1 reference

13 May 2018

Mori H

8

1 reference

13 May 2018

language of work or name

English

0 references

publication date

1 November 1999

1 reference

13 May 2018

published in

Urology

1 reference

13 May 2018

volume

54

1 reference

13 May 2018

issue

5

1 reference

13 May 2018

page(s)

829-833

1 reference

13 May 2018

describes a project that uses

magnetic resonance imaging

1 reference

alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia

inferred from title

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900258-7

7 January 2021

The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900258-7

7 January 2021

Prostatic carcinoma and benign prostatic hyperplasia: correlation of high-resolution MR and histopathologic findings

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900258-7

7 January 2021

Benign prostatic hyperplasia: value of MR imaging for determining histologic type

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900258-7

7 January 2021

Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900258-7

7 January 2021

Benign prostatic hyperplasia. Medical and minimally invasive treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900258-7

7 January 2021

Medical therapy for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900258-7

7 January 2021

Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900258-7

7 January 2021

Relationship of Symptoms of Prostatism to Commonly Used Physiological and Anatomical Measures of the Severity of Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900258-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900258-7

7 January 2021

Systematic sextant biopsies in 651 patients referred for prostate evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900258-7

7 January 2021

10.1016/S0090-4295(99)00258-7

Identifiers

DOI

1 reference

13 May 2018

release_iph3fgfyivegbd5rwc3fxonugy

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/iph3fgfyivegbd5rwc3fxonugy

24 November 2022

mapped directly with Wikidata item

1 reference

13 May 2018